- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome, Adult Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Diffuse Large B-Cell Lymphoma, Childhood Myelodysplastic Syndrome, Childhood Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Mantle Cell Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Salt Lake City, Utah • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,109
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- Cyclophosphamide, Psoralen, Thiotepa, Allogeneic bone marrow transplantation, In vitro-treated peripheral blood stem cell transplantation (PBSCT), Radiation Therapy (RT)
- Drug · Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • St Louis, Missouri • Houston, Texas
- Conditions
- Breast Cancer, Lymphoma
- Interventions
- questionnaires
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myelofibrosis
- Interventions
- Pegylated interferon alpha2a
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Transfusion Dependent Beta-thalassemia
- Interventions
- ST-400 Investigational product
- Genetic
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Oakland, California • Atlanta, Georgia + 3 more
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
- Interventions
- Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
- Procedure · Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 39 more
- Conditions
- Cancer
- Interventions
- aprepitant, dexamethasone, ondansetron, placebo
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Tagraxofusp-erzs
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome
- Biological · Other · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
- Interventions
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Tetanus
- Biological
- Lead sponsor
- Robert Krance
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
- Interventions
- Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis
- Drug · Device · Radiation + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 5 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Plasma Cell Myeloma
- Interventions
- Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
- Interventions
- ProTmune, Control Arm
- Biological
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
- Conditions
- Multiple Myeloma
- Interventions
- BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
- Drug
- Lead sponsor
- BioLineRx, Ltd.
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
- Conditions
- Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
- Interventions
- Eltrombopag Olamine, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Treosulfan
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
- Conditions
- Distress, Hematopoietic Stem Cell Transplantation
- Interventions
- Problem Solving Education
- Behavioral
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndrome, Mixed Phenotype Acute Leukemia
- Interventions
- Orca-T
- Biological
- Lead sponsor
- Orca Biosystems, Inc.
- Industry
- Eligibility
- Not listed
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Palo Alto, California • Tampa, Florida + 5 more
- Conditions
- Hematological Malignancies
- Interventions
- Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Fludarabine, Busulfan, Hematopoietic stem cell transplantation
- Radiation · Drug · Genetic
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Duarte, California • Tampa, Florida • Minneapolis, Minnesota + 5 more